A PHASE 1B, RANDOMIZED, DOUBLE-BLIND (SPONSOR-OPEN), PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACODYNAMICS AND PHARMACOKINETICS OF MULTIPLE ORAL DOSES OF PF- 06865571 FOR 2 WEEKS IN ADULTS WITH NONALCOHOLIC FATTY LIVER DISEASE
Phase of Trial: Phase I
Latest Information Update: 02 May 2019
Price : $35 *
At a glance
- Drugs PF 06865571 (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 Apr 2019 Status changed from recruiting to completed.
- 25 Mar 2019 Planned End Date changed from 5 Apr 2019 to 11 Apr 2019.
- 18 Feb 2019 Planned End Date changed from 20 Feb 2019 to 5 Apr 2019.